Alternate Title
Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Stage IV Mesothelioma
Basic Trial Information
 |
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
1 and over
|
|
|
|
Other
|
|
|
|
BC-MA-2
NCT00003508
|
| |
Trial Description
Purpose:
Antineoplastons are naturally-occurring substances that may also be made in the laboratory. Antineoplastons may inhibit the growth of cancer cells.
This phase II trial is studying how well antineoplaston therapy works in treating patients with advanced mesothelioma.
Eligibility:
Eligibility criteria include the following:
Final eligibility for a clinical trial is determined by the health professionals conducting the trial. For more details about the eligibility requirements for this trial and the treatment or intervention, refer to the Health Professional version of the trial summary.
Treatment/Intervention:
Patients will receive infusions of antineoplastons six times a day for as long as benefit is shown. Patients will be evaluated regularly.
Important:
If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.
Trial Contact Information
Trial Lead Organizations
Burzynski Clinic
|
|
|
| Stanislaw Burzynski, MD, PhD, Protocol chair |
|
|
|
